Swartz Robin 4
4 · Voyager Therapeutics, Inc. · Filed Feb 10, 2026
Research Summary
AI-generated summary of this filing
Voyager (VYGR) COO Robin Swartz Receives Stock Awards
What Happened
Robin Swartz, Chief Operating Officer & Chief Business Officer of Voyager Therapeutics (VYGR), was granted two awards on February 6, 2026: 45,000 restricted stock units (RSUs) and a 210,000-share stock option (reported as a derivative). Both grants are reported at $0.00 (i.e., awarded as compensation), not purchases or sales.
Key Details
- Transaction date: February 6, 2026; reported on Form 4 filed February 10, 2026 (filed within the typical two-business-day window).
- Price: $0.00 for both the RSU award and the option grant (reported value $0).
- Shares owned after transaction: Not specified in the filing provided.
- Footnote highlights:
- F1 (RSUs): 45,000 RSUs; each RSU converts to one share upon vesting. Vesting starts on the grant date (2/6/2026) and occurs over three years — 1/3 vests on the one-year anniversary, then 1/3 each year thereafter, subject to continued service.
- F2 (Option): 210,000-share stock option; vesting starts on the grant date (2/6/2026) and vests over four years on a monthly schedule (1/48th vests after one month, then monthly thereafter), subject to continued service.
- No indication of tax withholding, 10b5-1 plan, cashless exercise, or immediate sale in this filing.
Context
RSUs and stock options are common forms of executive compensation. RSUs convert to shares when they vest; options must be exercised (and may have an associated strike price not shown here) to become shares. These awards are compensation-related grants rather than open-market purchases or sales, so they primarily reflect company compensation decisions rather than an immediate insider buy/sell signal.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-06+45,000→ 214,647 total - Award
Stock Option (Right to Buy)
[F2]2026-02-06+210,000→ 210,000 totalExercise: $3.68Exp: 2036-02-06→ Common Stock (210,000 underlying)
Footnotes (2)
- [F1]Consists of shares of common stock issuable under an aggregate of 45,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.
- [F2]This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.